TIROCAP CAPSULE

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Beli sekarang

Ciri produk Ciri produk (SPC)
17-06-2021

Bahan aktif:

LEVOTHYROXINE SODIUM

Boleh didapati daripada:

IBSA INSTITUT BIOCHIMIQUE SA

Kod ATC:

H03AA01

INN (Nama Antarabangsa):

LEVOTHYROXINE SODIUM

Dos:

125MCG

Borang farmaseutikal:

CAPSULE

Komposisi:

LEVOTHYROXINE SODIUM 125MCG

Laluan pentadbiran:

ORAL

Unit dalam pakej:

100

Jenis preskripsi:

Prescription

Kawasan terapeutik:

THYROID AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0107794013; AHFS:

Status kebenaran:

APPROVED

Tarikh kebenaran:

2021-06-21

Ciri produk

                                _TIROCAP™ (levothyroxine sodium capsules) _
_Page 1 of 32_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TIROCAP™
Levothyroxine Sodium capsule
Capsules,13 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125
mcg,
137 mcg, 150 mcg, 175 mcg and 200 mcg, oral
Thyroid Hormone
ATC Code: H03AA01
Institut Biochimique SA (IBSA)
Via del Piano 266
CH-6915 Pambio-Noranco,
Switzerland
Imported by:
Progress Therapeutics Inc.
14-320 Harry Walker Parkway North
Newmarket ON
Canada, L3Y 7B4
Date of Initial Authorization:
November 25, 2020
Date of Revision:
June 17, 2021
Submission Control No: 248553
_ _
_TIROCAP™ (levothyroxine sodium capsules) _
_Page 2 of 32_
TABLE OF CONTENTS
TABLE OF
CONTENTS.......................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 4
1
INDICATIONS
...........................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics
..........................................................................................................
4
2
CONTRAINDICATIONS
...........................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................. 5
4
DOSAGE AND ADMINISTRATION
.........................................................................
5
4.1
Dosing
Considerations.....................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................. 6
4.3
Administration...................................................................................................
9
4.4
Missed
Dose.....................................................................................................
9
5
OVER
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Ciri produk Ciri produk Perancis 17-06-2021

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen